Cellectis said its board approved a strategic transformation on September 11, 2026, shifting the company toward in vivo gene editing for long-lasting treatments for chronic diseases. It will prioritize .HEAL-101, a TALE-base editor targeting APOC3 for severe hypertriglyceridemia, and .HEAL-201, a TALE-epigenetic modulator targeting the PCSK9 promoter for severe hypercholesterolemia. Preclinical humanized-mouse studies showed reductions of up to 70% in APOC3 and more than 90% in PCSK9, while triglycerides fell by up to 76% with .HEAL-101. Cellectis plans investigator-initiated Phase 1 trials in China, with preliminary data targeted for the second half of 2027 and first half of 2028, respectively. The company will stop developing its allogeneic CAR T-cell candidates lasme-cel and eti-cel while seeking partners, citing lower relapse rates in frontline treatment and growing competition from bispecific antibodies and in vivo CAR-T approaches. Cash, cash equivalents and fixed-term deposits totaled $169 million as of June 30, 2026, which was expected to fund operations into the fourth quarter of 2027 before the realignment; Cellectis now targets a runway into the second half of 2028. Its shares fell 27.42% to $2.250 on Monday, according to Benzinga Pro data.